Regeneron Pharmaceuticals Inc. (REGN)

Oncology Corporate Profile

Stock Performance


3 Month Stock History Chart

Data provided for free by IEX.

HQ Location

777 Old Saw Mill River Road
Tarrytown, NY 10591

Company Description

Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. Currently, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.


Brand Generic Indication
Libtayo®cemiplimab-rwlcLibtayo® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Zaltrap®afliberceptZaltrap®, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor1st line metastatic hormone-refractory Prostate cancer (HRPC)IIISanofi
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor2nd line metastatic Non Small Cell Lung Cancer (NSCLC)IIISanofi
REGN2810PD-1 antibodySquamous cell carcinoma of the Head & NeckIISanofi
Zaltrap® / aflibercept / VEGF TrapVEGF-A inhibitor1st line metastatic Colorectal cancerIISanofi
REGN2810 (+ Pexa-Vec)PD-1 antibodyRenal cell carcinoma (RCC)ISillaJen
enoticumab / REGN421anti-Dll4 antibodyVarious cancer typesISanofi
REGN2810PD-1 antibodyVarious cancer typesISanofi
REGN1979CD20XCD3 AntibodyVarious cancer typesI
REGN1979 (+ REGN2810)CD20XCD3 AntibodyVarious cancer typesI
REGN3767LAG-3 AntibodyVarious cancer typesISanofi

View additional information on product candidates here »


Recent News Headlines

FDA Rejects Sanofi/Regeneron’s Sarilumab

10/31/2016 03:41 pm

(PharmaTimes [UK]) Oct 31, 2016 - US regulators are refusing to approve Sanofi and Regeneron's sarilumab to treat patients with rheumatoid arthritis until certain manufacturing issues are addressed.

Weeks After Deal, FDA Slaps Clinical Hold on Regeneron/Teva Pain Drug

10/17/2016 04:34 pm

(Xconomy New York) Oct 17, 2016 - Regeneron Pharmaceuticals has seen its share of ups and downs over the years developing a drug for chronic pain that could represent an alternative to addictive opioids. And another roadblock just emerged this morning.

Regeneron, Teva Take Aim At Lilly/Pfizer Pain Drug

9/20/2016 05:22 pm

(The Daily Mail/Reuters) Sept 20, 2016 - Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics

8/2/2016 04:16 pm

(Yahoo! Finance) Aug 2, 2016 - Regeneron Pharmaceuticals, Inc. and Adicet Bio, Inc. announced today a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics.

Supreme Court’s Ruling In Patent Case A Blow To Drug Industry

6/20/2016 12:05 pm

(STAT) June 20, 2016 - The Supreme Court dealt a defeat to the pharmaceutical industry Monday in a closely watched patent law case that drug makers had argued endangered their continued investments in drug research and development.

Microsoft Finds Cancer Clues in Search Queries

6/8/2016 07:00 am

(New York Times) June 7, 2016 - Analyzing queries on Bing, researchers found warning signs of symptoms of pancreatic cancer before the disease was diagnosed.

Continuing Nivolumab Beyond Progression May Be Worthwhile in Kidney Cancer

5/20/2016 11:03 am

(Medscape Medical News/Reuters Health) May 19, 2016 - Nivolumab can be effective in patients with metastatic renal cell carcinoma (RCC) treated beyond first progression, according to a subgroup analysis of a phase 2 clinical trial.

Regeneron CEO Says Drug Price Critique by Independent Group Unscientific

5/13/2016 04:59 pm

(Reuters) May 12, 2016 - Regeneron Pharmaceuticals Chief Executive Leonard Schleifer on Thursday took aim at an influential drug pricing watchdog, saying a critique of the company's new cholesterol lowering therapy was non-scientific.

Regeneron, Intellia Partner to Develop CRISPR/Cas Therapeutics

4/12/2016 05:15 pm

(Genetic Engineering & Biotechnology News) Apr 11, 2016 - Regeneron Pharmaceuticals will license Intellia Therapeutics’ CRISPR/Cas gene-editing technology in a collaboration focused primarily on developing therapies for diseases that may be treated by editing genes in the liver, the companies said today.

MedImmune and Regeneron Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer

4/6/2016 02:43 pm

( Apr 5, 2016 - MedImmune, the global biologics research and development arm of AstraZeneca, and Regeneron Pharmaceuticals, Inc., today announced that they have entered into a licensing agreement under which Regeneron will use MedImmune's pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibody-drug conjugates (ADCs) as potential cancer treatments.

Regeneron's Skin-Clearing Drug Hits Goals in Late Trials

4/1/2016 04:40 pm

(Bloomberg) Mar 31, 2016 - Regeneron Pharmaceuticals Inc. and Sanofi said their drug to treat a serious skin condition met its goals in two final-stage trials, clearing the path toward regulatory approval in a potentially lucrative field.

Regeneron and Sanofi's Drug Study Meets Endpoint

3/23/2016 04:36 pm

(MarketWatch) Mar 23, 2016 - Regeneron Pharmaceuticals Inc. and Sanofi SA on Wednesday said its cholesterol-lowering drug in hereditary patients met its primary endpoint in a late-stage study.

Amgen Bests Regeneron in Patent Fight Over Cholesterol Drugs

3/17/2016 04:49 pm

(Bloomberg) Mar 16, 2016 - Amgen Inc. won a legal victory over Regeneron Pharmaceuticals Inc. in an intellectual property battle over their cholesterol-reducing drugs. Regeneron said it would appeal the decision.

Breakthrough in Cancer Research Could Spawn New Treatments

3/4/2016 11:03 am

(CNN) Mar 4, 2016 - Researchers discovered that even though cancer cells mutate wildly within a person's body, the cancer cells within each patient also have common mutations -- ones that could be isolated and fought off by certain immune cells.

Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial

3/1/2016 05:52 pm

(Bloomberg) Feb 27, 2016 - Regeneron Pharmaceuticals Inc.’s Eylea injection was no more effective in treating a severe eye disease than Roche Holding AG’s Lucentis after two years, according to findings from a new study that may not be enough to knock Regeneron off its dominant perch in the field.

Two Indian States Halt Sales Of Roche's Avastin Drug

1/19/2016 01:05 pm

(Reuters) Jan 19, 2016 - Two Indian states have put sales of Swiss drugmaker Roche's blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat.

Biden Pledges Faster U.S. Approval For Cancer Drug Cocktails

1/19/2016 01:04 pm

(Reuters) Jan 19, 2016 - U.S. Vice President Joe Biden said on Tuesday that the United States would speed up the approval of promising new drug combinations in his government's newly announced drive to cure cancer "once and for all”.

End-Of-Life Care Costs In US Comparable To Europe And Canada

1/19/2016 12:02 pm

(Forbes) Jan 19, 2016 - Published in JAMA, the report compares end-of-life care practices for patients dying with cancer in seven countries: Belgium, Canada, England, Germany, the Netherlands, Norway and the United States.

Researchers Advocate Improvements In End-Of-Life Care

1/19/2016 12:02 pm

(Dana-Farber) Jan 19, 2016 - Three Dana-Farber Cancer Institute researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.

Oncology Group Criticizes Insurers' Cancer Care Guidelines

1/19/2016 12:02 pm

(Pittsburgh Post-Gazette) Jan 19, 2016 - Doctors at the two leading health care systems in Pittsburgh — Allegheny Health Network and UPMC — use different guidelines to treat people with cancer, but they say their programs are not interfering with care, despite a warning by a professional group that such guidelines too often emphasize cost control over what’s best for the patient.

Baxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)

1/19/2016 12:02 pm

(TheStreet) Jan 19, 2016 - Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the European Commission has granted Marketing Authorization for use of ONCASPAR as a combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®

1/19/2016 12:02 pm

(IRX Therapeutics) Jan 19, 2016 - IRX Therapeutics, a clinical-stage bioresearch company developing cancer immunotherapies, and ImmunID, an immune molecular diagnostics and precision medicine company, today announced they have entered into a collaboration agreement for prediction of response to the IRX-2 immunotherapy candidate using the ImmunTraCkeR® assay.

Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and PIK3CA Tumor Mutations

1/19/2016 12:02 pm

(Morningstar) Jan 19, 2016 - Transgenomic, Inc. today announced the launch of the MX-ICP RAS Analysis and the MX-ICP PIK3CA Analysis, two new cancer panels based on the company’s Multiplexed ICE-COLD PCR™ (MX-ICP) technology.

MOLOGEN AG: First Combination Trial with MGN1703 and a Checkpoint Inhibitor in Collaboration with MD Anderson

1/19/2016 12:01 pm

(Yahoo! Finance) Jan 19, 2016 - The biotech company MOLOGEN AG today announced that it has entered into a collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson).

VP Joe Biden Says Politics Are Impeding Cancer Cure

1/19/2016 12:01 pm

(CBS News/Associated Press) Jan 15, 2016 - Vice President Joe Biden launched a "moonshot" initiative Friday to hasten a cure for cancer, aiming to use his final year in office to break down barriers in the medical world he says are holding back progress on eradicating the dreaded disease.

The Best Missions for a Cancer Moonshot

1/19/2016 12:01 pm

(New York Times/Room for Debate) Jan 19, 2016 - Some cancer researchers say the idea of curing cancer with a massive government program relies on an outmoded, simplistic model of the disease.

ASCO Official Participates in Vice President’s “Moonshot” Launch

1/19/2016 12:01 pm

(ASCO) Jan 15, 2016 - During Vice President Joe Biden’s formal launch today of his “moonshot” to cure cancer, the American Society of Clinical Oncology (ASCO) encouraged a comprehensive approach to accelerate the discovery of new cancer treatments, including issues related to enrollment in clinical trials, access to care, federal funding, and information technology and interoperability.

Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

1/19/2016 11:05 am

( Jan 19, 2016 - Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

Mayo Study: Radiation an Important Addition to Treatment for Pancreatic Cancer Surgery Candidates

1/19/2016 11:04 am

(Mayo Clinic) Jan 18, 2016 - Radiation therapy was associated with a lower risk of cancer recurrence in pancreatic cancer surgery patients, making it, like chemotherapy, an important addition to treatment, Mayo Clinic research found.

Pregabalin ‘Shouldn’t Be Prescribed As A Way To Control Bone Pain’

1/19/2016 11:04 am

(EPM News) Jan 19, 2016 - A drug used to treat bone pain caused by cancer makes little difference to patients’ well-being, according to research by the University of Edinburgh.

Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium

1/19/2016 11:04 am

(Merck) Jan 19, 2016 - Seven registration-enabling trials evaluating Keytruda in patients with gastrointestinal cancers are planned or underway.

Clovis Oncology Enters into Clinical Trial Collaboration

8/11/2015 11:05 am

(MarketWatch) Aug 11, 2015 - Study to evaluate the combination of rociletinib (CO-1686) with Genentech’s atezolizumab (MPDL3280A) for patients with advanced EGFR-mutant non-small cell lung cancer.

Sanofi to Join Regeneron in Quest to Unleash Immune System on Cancer

7/28/2015 04:45 pm

(New York Times) July 28, 2015 - The French pharmaceutical giant Sanofi will pay at least $1.7 billion to enter a new collaboration with Regeneron Pharmaceuticals, this one aimed at developing drugs that harness the body’s immune system to fight cancer.

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

7/28/2015 11:55 am

(Sanofi) July 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

The Challenges of Incorporating Gene Panels Into Clinical Practice

6/23/2015 11:01 am

(Medscape Oncology) June 22, 2015 - In the past several years, an increasing number of gene panel tests have become available for use in the clinic. At the recent annual meeting of the American Society of Clinical Oncology (ASCO), speakers discussed some of the controversies and clinical dilemmas surrounding these tests.

Higher Quality Screening Colonoscopies Associated With Lower Lifetime Risk of Colorectal Cancer and Death

6/17/2015 11:03 am

(Kaiser Permanente) June 16, 2015 - Kaiser Permanente study shows improved polyp screening saves lives without increasing overall cost of care.

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

6/12/2015 11:02 am

(Agios) June 12, 2015 - Agios Pharmaceuticals, Inc. presented today new, final data from its Phase 1 multiple ascending dose (MAD) clinical trial of AG-348 in healthy volunteers in an oral presentation at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna.

FDA Staff: Sanofi/Regeneron Drug Lowers LDL; Is Well Tolerated

6/5/2015 05:06 pm

(Reuters) June 5, 2015 - An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration.

Merck KGaA Sees Immunotherapy Drug Holding Its Own in Cancer Race

6/3/2015 11:02 am

(Reuters) June 1, 2015 - The head of Merck KGaA's healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types.